HNSCC Cells and PIK3CA Mutation

The PIK3CA mutations within the authors’ engineered cell model did not lead to enhanced oncogene-dependent cell death when treated with direct inhibition of the PI3K enzyme yet did show increased sensitivity compared with control with dual PI3K/mTOR inhibition. Additional study is required to develop new model systems and approaches to determine the role of targeted therapy in the treatment of PI3K-overactive HNSCC tumors.
Source: JAMA Otolaryngology - Head and Neck Surgery - Category: ENT & OMF Source Type: research

Related Links:

To report clinical features of bone metastases (BM) from head and neck squamous cell carcinoma (HNSCC).
Source: Auris, Nasus, Larynx - Category: ENT & OMF Authors: Source Type: research
In this study, we aimed to determine the potential clini...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
Head and neck squamous cell carcinoma (HNSCC) has a substantial risk of cervical lymph node metastases [1]. For small nodal metastases, it is not uncommon that they remain undetected (i.e. occult) because they fall below the detection threshold of diagnostic imaging [1,2]. In a clinically negative neck (cN0) the prevalence of occult metastases ranges between 10% and 35%, depending on the primary tumor site and T-stage [2]. To eradicate potential occult nodal disease, elective irradiation (typically an equivalent dose of 45 –50 Gy in 2-Gy fractions) to the clinically uninvolved nodal target volume (CTVelective-nodal...
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
In conclusion, this study elucidated that combination of cisplatin and XAV-939 exerted cytotoxic and genotoxic effect to abrogate CSC mediated chemoresistance in HNSCC in synergistic manner.
Source: Mutation Research Genetic Toxicology and Environmental Mutagenesis - Category: Genetics & Stem Cells Source Type: research
In this study, we identify that C188-9, a small-molecule STAT3 inhibitor, exhibits an antitumor effect on HNSCC in vitro. C188-9 significantly inhibits cell growth, arrests cell cycle at G0/G1 phase, and induces apoptosis in HNSCC. Besides, the capacities of migration and invasion of HNSCC cells are impaired with the exposure to C188-9. In addition, C188-9 treatment enhanced the chemosensitivity of HNSCC cellsin vitro. Moreover, C188-9 inactivates STAT3 by reducing its phosphorylation at Tyr705. Taken together, these results indicate that C188-9 could be a promising therapeutic strategy for patients suffered from HNSCC by ...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Preclinical Papers Source Type: research
ConclusionOur findings indicate that metabolic alterations, characteristic for malnutrition or cachexia, can be detected already at the beginning of the treatment, making it possible to monitor the patients with a higher risk of weight loss.
Source: Metabolomics - Category: Biology Source Type: research
Tracheal head and neck squamous cell cancer recurrence without metastases may be related to physical displacement of cancer cells. AbstractTracheal head and neck squamous cell cancer recurrence without metastases may be related to physical displacement of cancer cells.
Source: Clinical Case Reports - Category: General Medicine Authors: Tags: CASE REPORT Source Type: research
Condition:   Head and Neck Cancer Interventions:   Drug: AMD3100;   Drug: Pembrolizumab Sponsors:   Massachusetts General Hospital;   Merck Sharp & Dohme Corp.;   AperiSys, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Head and Neck Cancer Interventions:   Drug: AMD3100;   Drug: Pembrolizumab Sponsors:   Massachusetts General Hospital;   Merck Sharp & Dohme Corp.;   AperiSys, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Head and Neck Cancer Interventions:   Drug: AMD3100;   Drug: Pembrolizumab Sponsors:   Massachusetts General Hospital;   Merck Sharp & Dohme Corp.;   AperiSys, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: ENT & OMF | HNSCC | Study